Inhibition of tumor growth and angiogenesis by a lysophosphatidic acid antagonist in an engineered three‐dimensional lung cancer xenograft model
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We developed an engineered three‐dimensional (3D) tumor xenograft model of nonsmall cell lung cancer (NSCLC) in nude mice, and we used this model to evaluate a dual‐activity inhibitor of lysophosphatidic acid (LPA) biosynthesis and receptor activation. METHODS: First, BrP‐LPA, a pan‐antagonist for 4 LPA receptors and inhibitor of the lyosphospholipase D activity of autotaxin, was examined for inhibition of cell migration and cell invasion by human NSCLC A549 cells. Second, A549 cells were encapsulated in 3D in 3 semisynthetic extracellular matrices (ECMs) based on chemically modified glycosaminoglycans, and injected subcutaneously in nude mice. Tumor volume and vascularity were determined as a function of semisynthetic ECMs composition. Third, engineered NSCLC xenografts were formed from A549 cells in either Extracel‐HP or Matrigel, and mice were treated with 4 intraperitoneal injections of 3 mg/kg of BrP‐LPA. RESULTS: First, BrP‐LPA inhibited cell migration and invasiveness of A549 cells in vitro. Second, tumor growth and microvessel formation for 3D encapsulated A549 cells in vivo in nude mice increased in the following order: buffer only < Extracel < Extracel‐HP < Extracel‐HP containing growth factorss plus laminin. Third, tumor volumes increased rapidly in both Matrigel and Extracel‐HP encapsulated A549 cells, and tumor growth was markedly inhibited by BrP‐LPA treatment. Finally, tumor vascularization was dramatically reduced in the A549 tumors treated with BrP‐LPA. CONCLUSIONS: Engineered A549 lung tumors can be created by 3D encapsulation in an ECM substitute with user controlled composition. The engineered tumors regress and lose vascularity in response to a dual activity inhibitor of the LPA signaling pathway. Cancer 2010. © 2010 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Taking Cell-Matrix Adhesions to the Third Dimension
Cukierman, E., Pankov, R., Stevens, D. R., & Yamada, K. M. (2001) · Science · doi:10.1126/science.1064829 · Cited by 3,027 · cited 1×
“Cell-matrix interactions in 3D are an essential part of the microenvironment of all cells, including tumor cells.(50) The tumor-derived ECM product Matrigel has seen widespread use in distinguishing gene expression and phenotypic differences in cells growth in 3D(51) modeling tissue-specific signaling and organ functi…”
BackgroundBasement membrane complexes with biological activity
Kleinman, H. K., McGarvey, M. L., Hassell, J. R., Star, V. L., Cannon, F. B., Laurie, G. W., & Martin, G. R. (1986) · Biochemistry · doi:10.1021/bi00350a005 · Cited by 1,502 · cited 1×
“Delivery of tumor cells in Matrigel, a threedimensional (3D) extracellular matrix (ECM) extracted from murine sarcoma tissue, overcomes some of these shortcomings by providing a growth-enhancing environment that mimics the tumor microenvironment.(11) An alternative approach was the use of Extracel, an in situ-injectab…”
MethodCell adaptation to a physiologically relevant ECM mimic with different viscoelastic properties
Ghosh, K., Pan, Z., Guan, E., Ge, S., Liu, Y., Nakamura, T., Ren, X.-D., Rafailovich, M., & Clark, R. A. F. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2006.09.038 · Cited by 386
Cited by
G protein-coupled receptors: novel targets for drug discovery in cancer
Lappano, R., & Maggiolini, M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3320 · Cited by 717
Skardal, A., Devarasetty, M., Kang, H.-W., Mead, I., Bishop, C., Shupe, T., Lee, S. J., Jackson, J., Yoo, J., Soker, S., et al. (2015) · Acta Biomaterialia · doi:10.1016/j.actbio.2015.07.030 · Cited by 428
“These materials have been implemented in several bioprinting applications [7,9,11], as well as numerous other applications regenerative medicine, including acceleration of angiogenesis [27], adipose tissue engineering [28,29], vocal fold and bone repair [30–33], 3-D cell expansion and recovery [34], and engineering of…”
Prestwich, G. D. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.04.007 · Cited by 413
Self-citationThree-dimensional cell culturing by magnetic levitation
Haisler, W. L., Timm, D. M., Gage, J. A., Tseng, H., Killian, T. C., & Souza, G. R. (2013) · Nature Protocols · doi:10.1038/nprot.2013.125 · Cited by 298
Design of spherically structured 3D in vitro tumor models -Advances and prospects
Ferreira, L. P., Gaspar, V. M., & Mano, J. F. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.05.034 · Cited by 249
“Identically microparticles, microcapsules can be used as a means of incorporating specific ECM mimetic components allowing the establishment of in vivo like interactions between internalized cells and tumor ECM as shown by Xu and co-workers [219].”
BackgroundResultBioprinting Cellularized Constructs Using a Tissue-specific Hydrogel Bioink
Skardal, A., Devarasetty, M., Kang, H.-W., Seol, Y.-J., Forsythe, S. D., Bishop, C., Shupe, T., Soker, S., & Atala, A. (2016) · Journal of Visualized Experiments · doi:10.3791/53606 · Cited by 65
Metadata
- Authors
- Xu, X., & Prestwich, G. D.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2010-02-08
- Volume
- 116
- Issue
- 7
- Pages
- 1739-1750
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2084010197
- Cited by
- 90
- References
- 3
- FWCI
- 4.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.